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Neuroblastoma, a cancer of embryonal neural crest cells, is the 
most common solid tumor of early childhood. The majority of 
children with neuroblastoma are diagnosed with advanced disease 
that is poorly responsive to conventional chemotherapy (1). 
Several biological and genetic factors have been identified for 
this disease, including age at diagnosis, tumor stage, unfavorable 
histology, and the status of the v-myc myelocytomatosis viral 
related oncogene, neuroblastoma derived (MYCN) oncogene (1). 
MYCN gene amplification can be demonstrated in approximately 
20% of primary neuroblastomas, is accompanied by MYCN over-
expression, and is a powerful adverse prognostic indicator for this 
disease (2,3).
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 Background Although the prognostic value of the ATP-binding cassette, subfamily C (ABCC) transporters in childhood 
neuroblastoma is usually attributed to their role in cytotoxic drug efflux, certain observations have suggested 
that these multidrug transporters might contribute to the malignant phenotype independent of cytotoxic drug 
efflux.
 Methods A v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (MYCN)–driven transgenic mouse 
neuroblastoma model was crossed with an Abcc1-deficient mouse strain (658 hMYCN1/2, 205 hMYCN1/1 mice) 
or, alternatively, treated with the ABCC1 inhibitor, Reversan (n = 20). ABCC genes were suppressed using short 
interfering RNA or overexpressed by stable transfection in neuroblastoma cell lines BE(2)-C, SH-EP, and 
SH-SY5Y, which were then assessed for wound closure ability, clonogenic capacity, morphological differentiation, 
and cell growth. Real-time quantitative polymerase chain reaction was used to examine the clinical significance 
of ABCC family gene expression in a large prospectively accrued cohort of patients (n = 209) with primary 
neuroblastomas. Kaplan–Meier survival analysis and Cox regression were used to test for associations with 
event-free and overall survival. Except where noted, all statistical tests were two-sided.
 Results Inhibition of ABCC1 statistically significantly inhibited neuroblastoma development in hMYCN transgenic mice 
(mean age for palpable tumor: treated mice, 47.2 days; control mice, 41.9 days; hazard ratio [HR] = 9.3, 95% 
confidence interval [CI] = 2.65 to 32; P < .001). Suppression of ABCC1 in vitro inhibited wound closure (P < .001) 
and clonogenicity (P = .006); suppression of ABCC4 enhanced morphological differentiation (P < .001) and inhib-
ited cell growth (P < .001). Analysis of 209 neuroblastoma patient tumors revealed that, in contrast with ABCC1 
and ABCC4, low rather than high ABCC3 expression was associated with reduced event-free survival (HR of 
recurrence or death = 2.4, 95% CI = 1.4 to 4.2; P = .001), with 23 of 53 patients with low ABCC3 expression ex-
periencing recurrence or death compared with 31 of 155 patients with high ABCC3. Moreover, overexpression 
of ABCC3 in vitro inhibited neuroblastoma cell migration (P < .001) and clonogenicity (P = .03). The combined 
expression of ABCC1, ABCC3, and ABCC4 was associated with patients having an adverse event, such that of the 
12 patients with the “poor prognosis” expression pattern, 10 experienced recurrence or death (HR of recurrence 
or death = 12.3, 95% CI = 6 to 27; P < .001).
 Conclusion ABCC transporters can affect neuroblastoma biology independently of their role in chemotherapeutic drug 
efflux, enhancing their potential as targets for therapeutic intervention.
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The development of resistance to multiple cytotoxic drugs is a 
major cause of treatment failure in cancer patients, and members 
of the ATP-binding cassette (ABC) transporter superfamily, 
including ABC subfamilies B and C, member 1 (ABCB1 and 
ABCC1), may contribute to this phenomenon by active efflux of 
chemotherapeutic agents from cancer cells (4). We have previously 
shown (5,6), both retrospectively and prospectively, that high-level 
expression of ABCC1, but not ABCB1, is a powerful independent 
prognostic indicator of poor outcome in neuroblastoma (5,6). 
Furthermore, ABCC1 appears to be transcriptionally regulated by 
the MYCN oncogene in neuroblastoma cells (7,8). ABCC1 
extrudes a number of chemotherapeutic drugs used in the routine 
treatment of neuroblastoma, leading us and others to conclude that 
ABCC1 may influence clinical outcome by mediating resistance to 
cytotoxic drugs used during treatment [reviewed in (4,9)]. Using 
two independent preclinical models of neuroblastoma, we recently 
demonstrated that genetic or pharmacological inhibition of 
ABCC1 sensitizes tumors to treatment with cytotoxic drugs that 
are known ABCC1 substrates (10).
However, there is also circumstantial evidence (11) that ABC 
transporters contribute to aspects of tumor biology independently 
of their capacity to expel cytotoxic drugs. In our own studies of 
ABCC1 gene expression in primary untreated neuroblastoma, we 
have observed a small number of patients with favorable clinical 
stage neuroblastoma but with high-level expression of ABCC1 and 
rapidly progressive disease (unpublished results). Because of their 
favorable clinical staging, these patients did not receive chemo-
therapy; therefore, the association between high ABCC1 expres-
sion and clinical outcome cannot be explained in terms of 
ABCC1-mediated chemoresistance. Similarly, in a small retro-
spective study (12), we found that high levels of ABCC4 expression, 
like ABCC1, were associated with poor clinical outcome in neuro-
blastoma, and although that same study demonstrated that high 
levels of ABCC4 could protect neuroblastoma cells from the 
chemotherapeutic drug irinotecan in vitro, the patients in the 
study received neither irinotecan nor any other drugs known to be 
ABCC4 substrates. Those results also suggested that the prognostic 
significance of ABCC4 could not be explained in terms of ABCC4-
mediated cytotoxic drug resistance. These findings raised the 
possibility that high levels of ABCC1 and ABCC4, and potentially 
other ABC transporters, may contribute to poor outcome in 
neuroblastoma through functions additional to and independent of 
efflux of chemotherapeutic drugs.
To specifically address this hypothesis, we first examined the 
role of ABCC1 in tumor formation by inhibition or deletion of 
Abcc1 in a well-characterized mouse model of neuroblastoma. We 
also tested the effects of depleting ABCC1 and ABCC4 using 
short interfering RNA (siRNA), or ectopic expression of ABCC1 
and ABCC3, on cell motility, clonogenic capacity, differentia-
tion, and cell growth in cultured neuroblastoma cells. Because 
other members of the ABCC branch of the ABC family can also 
extrude a variety of relevant physiological substrates, we exam-
ined the relationship between expression of all ABCC family 
members and clinical outcome in a large cohort of prospectively 
accrued neuroblastoma patients who had been previously 
recruited to assess ABCC1, as well as in a large independent 
cohort.
CONTEXTS AND CAVEATS
Prior knowledge
Resistance to cytotoxic drugs is thought to be a major cause of 
treatment failure in childhood neuroblastoma, and members of the 
ATP-binding cassette (ABC) transporter superfamily may contrib-
ute to this phenomenon by active efflux of chemotherapeutic 
agents from cancer cells. However, ABC drug transporters may 
also contribute to tumor progression through other mechanisms 
besides drug efflux.
Study design
The activity of the transporter ABC subfamily C, member 1 (ABCC1) 
was studied in mice null for ABCC1 or treated with an ABCC1 inhibitor. 
ABCC genes were also suppressed in neuroblastoma cell lines with 
short interfering RNA. The association of ABCC expression in 
tumor specimens with event-free and overall survival was analyzed 
in 209 primary neuroblastoma patients.
Contribution
Inhibition of ABCC1 suppressed neuroblastoma development in 
mice and inhibition of ABCC1 and ABCC4 suppressed clonogenicity 
and other functions relevant to tumor progression in neuroblastoma 
cell lines. Higher expression of ABCC1 and ABCC4 and lower ABCC3 
expression were associated with higher rates of recurrence or 
death, as was the combined expression of all three transporters.
Implication
The ABC transporters ABCC1, 3 and 4 may contribute to poor out-
comes in neuroblastoma through functions other than their role in 
resistance to cytotoxic drugs.
Limitations
The precise cellular mechanisms by which ABC transporters con-
tribute to neuroblastoma progression are not yet known. In vivo 
experiments were only performed for the ABCC1 transporter but 
not for ABCC3 and ABCC4.
From the Editors
 
Materials and Methods
Transgenic and Knockout Mice and Treatment With 
Reversan
To examine the effect of ABCC1 on neuroblastoma development 
and progression, we used the hMYCN transgenic mouse, in which 
targeted expression of the hMYCN transgene to neuroectodermal 
tissue by use of a tyrosine hydroxylase promoter results in the 
development of neuroblastoma, which closely resembles the primary 
human disease (13). The transgenic mouse line was backcrossed 
for four generations to 129SVter mice (Animal Resources Centre, 
Perth, Australia) and maintained as an inbred line at Children’s 
Cancer Institute Australia (14), with all subsequent male and 
female experimental mice being derived from this breeding colony. 
All mice that carry two copies of the transgene (ie, homozygous) 
develop tumors within a narrow 12-day window around 6 weeks 
of age. Recently, we identified a nontoxic, potent, and bioactive 
small-molecule inhibitor of ABCC1, designated Reversan, which 
enhanced the therapeutic efficacy of ABCC1-substrate drugs in 
tumor-bearing hMYCN transgenic mice (10). For ABCC1 inhibi-
tion studies, Reversan was obtained from ChemBridge Corp (San 
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Diego, CA). Weaned 3-week-old hMYCN transgenic mice were 
randomly assigned to treatment in a 5-day on and 2-day off schedule 
with either 10 mg/kg Reversan solubilized in dimethyl sulfoxide 
(DMSO) delivered by intraperitoneal injection (n = 20) or with 
equivalent amounts of the vehicle under the same schedule (control, 
n = 9), until a medium-sized palpable tumor (1 cm2) was detected. 
This experimental design had more than 80% statistical power to 
detect a delay in tumor formation of at least 12%, at a = .05.
The hMYCN transgenic mice were crossed with Abcc12/2 mice 
(C57 Bl/6 background), which have both alleles of Abcc1 inacti-
vated by homologous recombination (15). Offspring that were 
hMYCN1/2Abcc11/2 were mated, and the resulting hMYCN1/2Abcc11/2 
offspring were then backcrossed four times to 129X1/SV mice 
(Jackson Laboratory, Bar Harbor, ME). A total of 658 hMYCN1/2 
mice (160 Abcc11/1, 329 Abcc11/2, and 169 Abcc12/2), in addition to 
205 hMYCN1/1 mice (50 Abcc11/1, 106 Abcc11/2, and 49 Abcc12/2), 
all on a 129 background, were followed to study variations in 
tumor incidence and latency associated with presence or absence 
of functional Abcc1 alleles. Mice were palpated twice weekly and 
were killed by cervical dislocation or carbon dioxide–mediated as-
phyxiation when a medium-sized (1 cm2) palpable tumor was 
detected. Tumor incidence was followed until the detection of a 
tumor or until 20 weeks of age. This experimental design afforded 
statistical power of at least 80% to detect a twofold decrease in 
tumor incidence at a = .05 in a dominant genetic model.
All experimental procedures involving transgenic mice were 
approved by the University of New South Wales Animal Care and 
Ethics Committee according to the Animal Research Act, 1985 
(New South Wales, Australia) and the Australian Code of Practice 
for Care and Use of Animals for Scientific Purposes (1997).
Gene Silencing, Transfection, and Cellular Assays
Human neuroblastoma cells BE(2)-C, SH-EP, and SH-SY5Y were 
obtained from the laboratory of Barbara Spengler (Fordham 
University, New York, NY) (16,17) and cultured in Dulbecco’s mod-
ified Eagle medium (DMEM) containing 10% heat-inactivated 
fetal bovine serum and 2 mM glutamine. SH-EP cells were pas-
saged 6–8 times before use. The identities of the BE(2)-C and 
SH-SY5Y lines were verified by short tandem repeat genetic pro-
filing (CellBank Australia, Sydney, Australia).
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA) was 
used to deliver SMARTpool siRNA or individual siRNA duplexes 
for ABCC1 (1–10 nM), ABCC4 (1–10 nM), or siCONTROL non-
targeting pool siRNA (Dharmacon, Lafayette, CO) alone or in 
combination. For each cell line, siRNA transfection conditions 
were optimized using a green fluorescent protein–labeled siRNA 
duplex and flow-assisted cell sorting to determine conditions that 
would achieve transfection of at least 80% of cells. The siRNA 
sequences used as individual duplexes were, for ABCC1 suppres-
sion in SH-EP cells, ABCC1 SMARTpool duplex 1 (sense): 
GAUGACACCUCUCAACAAAdTdT; and for ABCC4 suppres-
sion in BE(2)-C cells, ABCC4 SMARTpool duplex 1 (designated 
ABCC4.1) (sense): GGACAGCCCUCGACCUUAAdTdT; or an 
independent sequence reported by Reid et al. (18), herein desig-
nated ABCC4 duplex 5 or ABCC4.5 (sense): GAUGGUGCAU 
GUGCAGGAUdTdT (18). For constitutive expression of ABCC1 
in SH-SY5Y cells, transfection with pCMV14-3xFLAG-ABCC1, 
or the ATP-binding site mutants, pCMV14-3xFLAG-ABCC1-
D1454N or ABCC1-DE1454LL, was followed by selection of 
stable clones with 500 µg/ml G418 (Geneticin; Invitrogen Australia 
Pty Ltd, Mulgrave, Australia), which were subsequently main-
tained with 150 µg/ml G418. The ABCC1-D1454N mutation was 
previously shown to abolish ATP-dependent ABCC1 transporter 
activity while not affecting correct localization of the transporter 
(19), and the ABCC1-DE1454LL mutant was predicted to have 
similar properties (Supplementary Figure 1, available online and 
http://www.uniprot.org/uniprot/O15439; accessed June, 2010). For 
stable clones expressing ABCC3, BE(2)-C cells were transduced 
with retroviral pCMV14-3xFLAG-ABCC3 or the ATP-binding 
site mutant, pCMV14-3xFLAG-ABCC3-V1322F. The V1322F 
mutation was predicted to abolish transporter activity while still 
being localized in the plasma membrane and is based on studies 
involving the closely related transporter, ABCC6, in which a single 
amino acid change in a region N-terminal to the Walker A motif 
in the second ABC domain abolishes catalytic activity (20) while 
retaining correct membrane localization in mammalian cell lines 
(Andras Varadi, personal communication). In this region, there is 
high sequence conservation with ABCC3. Localization of ABCC1 
and ABCC3 variants to the plasma membrane was verified by im-
munocytochemical staining for the FLAG epitope (Supplementary 
Figures 1 and 2, available online). After G418 selection, pooled 
or cloned transfectants were examined for protein expression by 
western blot and immunocytochemistry. Control cells were stably 
transduced with an empty vector.
Generation of ATP-binding site mutants was carried out 
according to the QuikChange Lightning Site-Directed Mutagenesis 
Kit (Stratagene, La Jolla, CA) using forward primer 5′-ATC CTT 
GTG TTG AAT GAG GCC ACG GCA G-3′ for ABCC1-D1454N 
(single mutant), forward primer 5′-ATC CTT GTG TTG CTT 
CTG GCC ACG GCA G-3′ for ABCC1-DE1454/1455LL (double 
mutant) and forward primer 5′-AGG TGG GGA TCT TCG 
GCC GCA CTG G-3′ for ABCC3-V1322F.
Whole-cell extracts were prepared using lysis buffer (50 mM 
Tris pH 7.4, 150 mM NaCl, 0.2% NP-40, 50 mM NaF, 5 mM 
EDTA, 0.1 mM orthovanadate, plus protease inhibitor cocktail 
[Sigma]) as described previously (21). To analyze the expression of 
ABCC3 protein, membrane-enriched fractions were prepared using 
a published protocol (22). Western blots were performed according 
to standard procedures as previously described (5) using 20–50 µg of 
whole-cell or membrane extracts. The antibodies used were against 
ABCC1 (rat monoclonal MRPr1; Alexis Biochemicals, CA; 1:500), 
ABCC3 (mouse monoclonal M3II-21; Abcam number ab3376; 
Cambridge, MA; 1:750), ABCC4 (rat monoclonal M4I-10; Alexis 
Biochemicals; 1:1000), FLAG epitope (anti-FLAG mouse mono-
clonal M2; Sigma, St Louis, MO; 1:1000), ß-actin (rabbit polyclonal 
A2066; Sigma; 1:2000), and α-tubulin (mouse monoclonal DM1A; 
Sigma; 1:3000). Immunocytochemistry was performed using mouse 
monoclonal anti-FLAG M2 (Sigma) and Cy3-conjugated goat 
anti-mouse (Jackson Immuno Research, West Grove, PA). Nuclei 
were stained with Hoechst 33258 (Sigma). The intracellular locali-
zation of ABCC proteins was assessed using a conventional epifluo-
rescence microscope (Eclipse 90i; Nikon Instruments, Melville, 
NY) equipped with a digital CCD camera. Image collages were 
made using Adobe Photoshop (Adobe System, Inc., San Jose, CA).
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Unless otherwise stated, all means were derived from at least 
three experiments. For wound closure assays, cell-free areas were 
generated by use of either a pipette tip or removal of a wound assay 
chamber (IBIDI, Martinsried, Germany) 48–72 hours after siRNA 
transfection or 2–6 hours after Reversan (5 µM) addition, and once 
a confluent monolayer was present. Growth medium (DMEM) 
was replaced (with medium containing Reversan where applicable) 
and two or three wound areas per condition were photographed at 
24  or 48 hours. Wound size was quantified by measuring the cell-
free areas using Image-J software (National Institutes of Health, 
Bethesda, MD). To quantify neurite outgrowth, after 72-hour 
exposure to siRNA, cells with one or more neuritic extensions of 
at least twice the length of the cell body were scored as positive. At 
least 100 cells were counted per random field, with at least four 
fields taken per treatment in each of three separate experiments. 
Colony-forming assays were performed as previously described 
(23), with cells replated 24 hours following siRNA transfection and 
colonies of greater than 100 cells counted. Alternatively, 24 hours 
after plating, SH-EP cells were exposed to 5 µM Reversan for 
72 hours and colonies counted 7 days after plating. DNA synthesis 
was monitored after 72-hour exposure to siRNA or 24-hour expo-
sure to 5 µM Reversan. Cells in 12-well plates were cultured in the 
presence of 0.5 µCi of 3H-thymidine and a 500-fold excess of unla-
beled thymidine for 5 hours before harvesting for radioassay in 
triplicate by liquid scintillation counting. Bromodeoxyuridine (BrdU) 
incorporation was measured using a Delfia Cell proliferation kit 
(AD0200; Perkin Elmer, Waltham, MA). Cell clones were plated 
in 96-well plates at a cell density of 15 000 cells per well with 200 µL 
DMEM medium and cultured for 48 hours before addition of 
BrdU for 2–12 hours, followed by triplicate assay according to the 
manufacturer’s protocol.
Patients and Tumor Specimens
The children in this study were enrolled in Pediatric Oncology 
Group (POG) Neuroblastoma Biology Study 9047 through 
POG-affiliated locations in North America, Switzerland, and 
Australia and were treated according to disease stage, age, and 
tumor biology, as specified in institutional as well as different 
POG protocols (5). To be eligible for POG Study 9047, patients 
were required to be 21 years of age or younger, newly diagnosed 
with pathological confirmation of neuroblastoma, to have 
informed consent, and to submit a blood or tumor specimen. 
Patients were consecutively accrued and, at the time of analysis, 
those specimens for whom clinical follow-up data were unavail-
able were excluded from the study. The final cohort comprised 
209 patients (205 enrolled between 1996 and 1998 and four 
patients enrolled between 1994 and 1995). This study population 
was found to be representative of patients with neuroblastoma in 
general with respect to well-established prognostic indicators, 
including MYCN amplification status, age at diagnosis, and 
tumor stage (Supplementary Figure 3, available online). The 
median period of follow-up for surviving patients was 55 months 
(range 0–196 months), whereas the median time from diagnosis to 
death among the patients with treatment failure was 18 months 
(range 0–60 months). All deaths except for five (two attributable 
to infection and three to hemorrhage) were disease related. The 
protocol was approved by individual institutional review boards, 
and informed consent was obtained for every patient registered in 
the study.
Gene Expression Analyses
RNA was extracted using TRIZOL reagent (Life Technologies, 
Mulgrave, Australia) and reverse transcribed with Moloney murine 
leukemia virus reverse transcriptase (Life Technologies) according 
to the manufacturer’s protocols, as previously described (5). Gene 
expression was determined by real-time quantitative polymerase 
chain reaction for 40 cycles using the ABI PRISM 7700 and ABI 
7900HT sequence detection systems (Applied Biosystems, Foster 
City, CA). For each gene, transcript quantification was based on 
the comparative threshold cycle method, or DDCt method, which 
compares the expression of a target gene normalized to the expres-
sion of a reference gene (in our case ß2-microglobulin), to provide 
relative quantification (24). As a positive control for each assay, 
cDNA derived from either the IMR-32 or SH-EP neuroblastoma 
cell lines was included in the experiment. Primer and probe 
sequences for ß2-microglobulin (internal control), ABCC1, and ABCC4 
(5,12) are listed, along with the remaining genes in Supplementary 
Table 1 (available online). Genes with a mean Ct value of 35 or 
greater in a set of 16 tumors (representative in terms of clinical 
parameters such as MYCN amplification status, stage, and clinical 
outcome) were not studied further.
Statistical Procedures
Differences in polymerase chain reaction values for a given target 
gene or phenotypic traits between groups were assessed by 
two-sided Student t tests. In the case of BrdU or 3H-thymidine 
incorporation assays, one-sample Student t tests were used to com-
pare between control and treated samples, where the control was 
assigned a value of 100%. For experiments involving more than 
two groups, one-way analysis of variance (ANOVA) was performed 
and, in cases where significant differences were detected, followed 
by pairwise t tests as indicated. Associations between clinical char-
acteristics of patients and molecular characteristics of tumors were 
examined using Fisher’s exact test. Event-free survival time was 
calculated as the time from diagnosis until the first occurrence of 
disease relapse, progression, death from any cause, or until last 
contact if no event occurred. Overall survival was the time from 
diagnosis until death or until last contact if the patient did not die. 
Survival analyses using SAS Version 9 (SAS Institute, Inc, Cary, 
NC) were performed according to the method of Kaplan and 
Meier (25) with SEs according to Peto and Peto (26) and compar-
isons of survival curves made using two-sided log-rank tests. 
Multivariable Cox regression analyses were performed to deter-
mine whether ABCC1, ABCC3, and ABCC4 gene expression were 
independently statistically predictive of event-free or overall sur-
vival. For the publicly available microarray dataset, clinical, patho-
logical, and gene expression data for 251 primary neuroblastoma 
tumors (27) were downloaded via http://pob.abcc.ncifcrf.gov/cgi-
bin/JK; accessed January, 2009. Kaplan–Meier survival analyses 
were performed using StatView 4.1 (Abacus Concepts, Inc, Berkeley, 
CA). Probabilities of survival and hazard ratios (HRs) are given with 
95% confidence intervals (CIs). Proportionality was confirmed 
by visual inspection of the plots of log(2log(S(time))) vs log(time), 
which were observed to remain parallel. P values less than .05 were 
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considered statistically significant. The clinical characteristics and 
outcomes of the patients were masked from the laboratory staff 
performing the gene expression analyses. For each of the genes 
analyzed, a continuous range of polymerase chain reaction values 
was obtained for the cohort of tumors. For a given gene, to cate-
gorize expression as either high or low, the cohort was repeatedly 
divided into two groups, with cut points at each quartile and at the 
lower and upper deciles of expression. For each cut point, a Cox 
model produced a P value and hazard ratio. Of the cut points with 
P < .05, the one with the highest hazard ratio was selected as the 
optimal expression cut point. This methodology has been described 
in detail in London et al. (28).
Results
Pharmacological or Genetic Attenuation of ABCC1 and 
Neuroblastoma Development In Vivo
To examine the effect of ABCC1 on neuroblastoma development 
and progression, we administered Reversan to hMYCN transgenic 
mice (n = 20; control group, n = 9) homozygous for the hMYCN 
transgene immediately after weaning but before macroscopic 
tumor development and in the absence of chemotherapeutic 
agents. We observed a statistically significant delay in tumor pro-
gression (mean age at occurrence of palpable abdominal tumor: 
treated mice, 47.2 days; vehicle-treated control mice, 41.9 days; 
HR = 9.3, 95% CI = 2.65 to 32; P < .001; Figure 1, A). To explore 
the role of ABCC1 in tumorigenesis, mice lacking the Abcc1 gene 
(Abcc12/2) were crossed with hMYCN transgenic mice and the 
progeny monitored for tumor formation. Loss of one allele of 
Abcc1 (Abcc11/2), and hence reduced expression of ABCC1 
(Supplementary Figure 4, available online), resulted in an increase 
in tumor latency in mice homozygous for the hMYCN transgene 
by comparison with wild-type (wt) Abcc11/1 mice (mean age for 
occurrence of palpable abdominal tumor: Abcc11/1 mice [n = 50], 
8.2 weeks; Abcc11/2 mice [n = 106], 9.2 weeks; HR = 1.63, 95% 
CI = 1.24 to 2.7; P = .003). Surprisingly, the statistical significance 
of this effect was lost upon complete deletion of Abcc1 (mean age 
for occurrence of palpable abdominal tumor: Abcc11/1 mice [n = 50], 
8.2 weeks; Abcc12/2 mice [n = 49], 8.6 weeks; HR = 1.1, 95% CI = 
0.7 to 1.6; P = .7). Loss of one allele of Abcc1 also decreased tumor 
incidence in mice hemizygous for hMYCN by comparison with 
mice possessing both alleles of Abcc1 (tumor incidence: Abcc11/2 
mice [n = 329], 12%; Abcc11/1 mice [n = 160], 21%; OR = 1.88, 
95% CI = 1.13 to 3.11; P = .02, Fisher exact test; Figure 1, B). In 
mice completely lacking Abcc1, there was no further impact on 
incidence by comparison with mice lacking one allele of Abcc1 
(tumor incidence: Abcc11/2 mice [n = 329], 12%; Abcc12/2 mice 
[n = 169], 15%; OR = 1.3, 95% CI = 0.77 to 2.24; P = .33, Fisher 
exact test; Figure 1, B).
ABCC1 and ABCC4 Expression and Neuroblastoma Cell 
Biology
In light of these observations and our previous finding that high 
ABCC4 expression is associated with poor outcome in neuroblas-
toma patients not treated with any drugs known to be substrates of 
ABCC4 (12), we sought to investigate the roles of ABCC1 and 
ABCC4 in neuroblastoma cell biology. Efficient depletion of 
ABCC1 and ABCC4 was achieved using siRNA in the MYCN-
amplified human neuroblastoma cell line, BE(2)-C (Figure 2, A).
ABCC1 depletion led to impaired cell motility, as measured by 
the ability to move into an artificial wound (mean % of wound 
open ± 95% CI: ABCC1, 38.6 ± 6.9 vs control, 7.0 ± 3.5, P < .001, 
two-sided Student t test, four independent experiments; Figure 2, 
B and C). The decreased wound-filling ability was attributable to 
impaired cell motility rather than decreased proliferation, because 
cells depleted of ABCC1 showed only a modest, although statisti-
cally significant decrease in thymidine incorporation (mean % of 
control ± 95% CI: ABCC1, 91.7 ± 1.4; P = .01, one-sample Student 
t test, three independent experiments; Figure 2, D). The BE(2)-C 
cells depleted of ABCC1 also displayed a substantial impairment in 
colony-forming ability (mean number of colonies ± 95% CI: 
ABCC1, 19.8 ± 2.7 vs control, 26.0 ± 3.3, P = .006, two-sided 
Student t test, three independent experiments; Figure 2, E), 
whereas morphological differentiation, as assessed by neurite 
extension, was only slightly increased (mean % neurite-positive 
cells ± 95% CI: ABCC1, 4.3 ± 0.78 vs control, 2.0 ± 0.4, P = .02, 
two-sided Student t test, three independent experiments; Figure 2, F).
By contrast with ABCC1, depletion of ABCC4 from BE(2)-C 
cells resulted in markedly increased morphological differentiation 
(mean % neurite-positive cells ± 95% CI: ABCC4, 14.2 ± 2.4 vs 
control, 2.0 ± 0.4, P < .001, two-sided Student t test, three inde-
pendent experiments; Figure 2, F). ABCC4 depletion was also 
associated with substantially decreased thymidine incorporation 
(mean % of control ± 95% CI: ABCC4, 62.3 ± 5.5, P = .005, one-
sample t test, three independent experiments; Figure 2, D) and 
colony-forming ability (mean number of colonies ± 95% CI: 
ABCC4, 17.8 ± 2.6 vs control, 26.0 ± 3.3, P < .001, two-sided 
Student t test, three independent experiments; Figure 2, E). There 
was also some impairment of cell motility in ABCC4-depleted cells 
(mean % of wound open ± 95% CI: ABCC4, 26.5 ± 8.0 vs control, 
Figure 1. Role of ABCC1 in neuroblastoma formation in vivo. A) 
Administration of ABCC1 inhibitor, Reversan (triangles), and tumor 
formation in homozygous hMYCN transgenic mice (n = 20) and vehicle-
treated controls (n = 9, DMSO; squares). B) Loss of one Abcc1 allele 
(Abcc11/2) and tumor incidence in hemizygous hMYCN transgenic mice 
(hMYCN1/2) compared with mice possessing both alleles of Abcc1 
(Abcc11/2 mice, n = 329, Abcc11/1 mice, n = 160, P = .02, two-sided 
Fishers exact test). Effect of loss of the second allele (Abcc12/2) com-
pared with mice lacking one allele of Abcc1 (Abcc11/2 mice, n = 329, 
Abcc12/2 mice, n = 169, P = .33; two-sided Fisher exact test). Abcc1 = 
ATP-binding cassette, subfamily C, member 1; DMSO = dimethyl sulf-
oxide; hMYCN = human v-myc myelocytomatosis viral related onco-
gene, neuroblastoma derived.
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7.0 ± 3.5, P < .001, two-sided Student t test, four independent 
experiments, Figure 2, C). Combined suppression of ABCC1 and 
ABCC4 in BE(2)-C cells had no further impact on the magnitude 
of effect for any of these properties (Figure 2, B–F).
Consistent with a role for ABCC1 in cell motility, MYCN non-
amplified SH-SY5Y neuroblastoma cells, which have relatively low 
levels of MYCN and ABCC1 (29,30), displayed considerably 
enhanced migratory ability when expressing high levels of exoge-
nous ABCC1 in two independent clones: ABCC1 D5 wt and 
ABCC1 H7 wt (mean % of wound open ± 95% CI: ABCC1 D5 wt, 
8.3 ± 5.3 or ABCC1 H7 wt, 13.3 ± 0.4 vs empty vector, 59.9 ± 9.6, 
P < .001, one-way ANOVA and two-sided t test, three independent 
experiments, Figure 3, A–C, Supplementary Figure 1, available 
online). ABCC1 transporter activity is necessary for the observed 
effects on cell motility, because forced expression of catalytically 
inactive ABCC1 (ABCC1-D1454N clone B4 or ABCC1-DE1454LL 
clone B7) had no impact on cell motility (mean % of wound 
open ± 95% CI: ABCC1 B4, 49.6 ± 4.5 vs empty vector, 59.9 ± 9.6, 
P = .08; ABCC1 B7, 55.6 ± 9.0 vs empty vector, 59.9 ± 9.6, 
P = .54, one-way ANOVA and two-sided t test, three independent 
Figure 2. Impact of ABCC1 and ABCC4 suppres-
sion in BE(2)-C human neuroblastoma cells. A) 
Western blot analysis of ABCC1 and ABCC4 
protein expression following exposure of 
BE(2)-C cells to ABCC1- and ABCC4-specific 
siRNA molecules, alone or in combination, or 
to control siRNA (lane 1). B) Representative 
images of wound closure assay; Scale bar = 
125 µm. C) Quantification demonstrating 
impaired motility of BE(2)-C cells depleted of 
ABCC1, ABCC4, or both, as measured by 
wound closure assay for 48 hours. D) 
3H-thymidine incorporation assay in BE(2)-C 
cells depleted of ABCC1, ABCC4, or both. E) 
Clonogenic capacity of BE(2)-C cells upon de-
pletion of ABCC1 and ABCC4 was assayed after 
10 days. F) Neurite extension in BE(2)-C cells 
upon depletion of ABCC1 and ABCC4. In panels 
(C), (E), and (F), P values were derived from 
two-sided Student t test vs control, whereas 
one-sample t test (H0, µ = 100%) was used in 
panel (D). Means are derived from at least 
three independent experiments. Error bars 
represent 95% confidence intervals. ABCC = 
ATP-binding cassette, subfamily C; siRNA = 
short interfering RNA.
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experiments; Figure 3, C). High-level expression of ABCC1 in 
these cells also enhanced colony-forming ability (mean number of 
colonies ± 95% CI: ABCC1 D5 wt, 97.6 ± 21.8 or ABCC1 H7 wt, 
97.0 ± 18.0 vs empty vector, 73.9 ± 4.3, P = .03, one-way ANOVA 
and two-sided t test, four independent experiments; Figure 3, D). 
This effect was completely abrogated in cells overexpressing the 
mutant ABCC1 carrying a single amino acid change in the ABC 
domain (D1454N) or the catalytically inactive double mutant of 
ABCC1 (DE1454LL) (mean number of colonies ± 95% CI: 
ABCC1 B4, 74.8 ± 1.6 vs empty vector, 73.9 ± 4.3, P = .96; ABCC1 
B7, 73.5 ± 5.9 vs empty vector, 73.9 ± 4.3, P = .88; one-way 
ANOVA and two-sided t test, four independent experiments; 
Figure 3, D). Overexpression of ABCC1 did not affect BrdU in-
corporation in SH-SY5Y cells (mean % of empty vector ± 95% CI: 
ABCC1 D5 wt, 96.5 ± 12.7; ABCC1 H7 wt, 93.7 ± 11.8, P = .68, 
one-way ANOVA, three independent experiments; Supplementary 
Figure 5, A, available online).
Next, we examined the impact of genetic or pharmacological 
suppression of ABCC1 in the MYCN nonamplified neuroblastoma 
cell line, SH-EP. Again, siRNA-mediated ABCC1 depletion 
impaired motility (mean % wound open ± 95% CI: ABCC1, 22.7 
± 2.4 vs control, 7.8 ± 4.1, P = .01, two-sided Student t test, three 
independent experiments; Figure 3, G) and colony-forming ability 
(mean number of colonies ± 95% CI: ABCC1, 48.5 ± 1.0 vs con-
trol, 60.0 ± 2.0, P = .01, two-sided Student t test, two independent 
experiments, each with two internal replicates; Figure 3, H) of 
SH-EP cells, whereas the relatively minor effect on thymidine 
incorporation observed in BE(2)-C cells was not apparent in SH-EP 
cells (mean % of control ± 95% CI: ABCC1, 98.4 ± 15.7, P = .86, 
one-sample Student t test, three independent experiments; 
Supplementary Figure 5, B, available online). Inhibition of ABCC1 
by Reversan had even more pronounced effects, in terms of 
reduced wound closure (mean % wound open ± 95% CI: Reversan, 
25.0 ± 11.0 vs DMSO, 4.3 ± 1.8, P = .01, two-sided Student t test, 
three independent experiments; Figure 3, I and J) and colony-
forming ability (mean number of colonies ± 95% CI: Reversan, 
58.7 ± 12.3 vs DMSO, 124.7 ± 24.7, P = .01, two-sided Student 
t test, three independent experiments, Figure 3, K), than siRNA-
mediated ABCC1 suppression, and also in terms of decreased 
thymidine incorporation (mean % of DMSO control ± 95% CI: 
Reversan, 65.0 ± 12.9, P = .033, one-sample Student t test, three 
independent experiments; Supplementary Figure 5, C, available 
online). In addition to a reduction in colony number, inhibition of 
ABCC1 by Reversan also resulted in an effect on colony size, 
whereby a greater proportion of large (>300 cells) colonies were 
noted in the controls compared with colonies arising from 
Reversan-treated SH-EP cells (mean number of large colonies ± 
95% CI: DMSO, 99 ± 29.4 vs Reversan, 33 ± 7.25, P = .01, 
two-sided Student t test, three independent experiments; 
Supplementary Figure 5, D, available online). Thus, modulation of 
ABCC1 by siRNA-mediated suppression, forced expression, or 
pharmacological inhibition, consistently affected cell motility and 
clonogenicity in three different neuroblastoma cell lines.
The phenotypic changes observed upon depletion of ABCC4 in 
BE(2)-C cells using SMARTpool siRNA, involving enhancement 
of neurite extension and accompanied by decreased thymidine 
incorporation and colony formation, were investigated further by 
targeting ABCC4 with individual siRNA duplexes and by exam-
ining the effect of ABCC4 suppression in an independent cell line 
SH-SY5Y. Of the four SMARTpool component duplexes (desig-
nated duplex 1 through 4), only duplex 1 was found to effectively 
suppress ABCC4 expression (Supplementary Figure 6, A, available 
online; data not shown). However, efficient suppression of ABCC4 
expression was also achieved using an independent sequence tar-
geting ABCC4 (18) (Supplementary Figure 6, A, available online, 
ABCC4.5). Using either of these sequences to target ABCC4 in 
BE(2)-C cells, even more pronounced effects on neurite extension 
(mean % neurite-positive cells ± 95% CI: ABCC4.1, 17.8 ± 4.9 or 
ABCC4.5, 27.3 ± 3.3 vs control, 2.6 ± 1.6, P < .001, one-way 
ANOVA and two-sided t test, three independent experiments; 
Supplementary Figure 6, B, available online), thymidine incorpo-
ration (mean % of control ± 95% CI: ABCC4.1, 55.0 ± 11.4, 
P =.004; ABCC4.5, 45.9 ± 20.6, P = .014, one-way ANOVA and 
one-sample t test, three independent experiments; Supplementary 
Figure 6, C, available online), and colony formation (mean number 
of colonies ± 95% CI: ABCC4.1, 27.6 ± 3.9 or ABCC4.5, 30.8 ± 9.6 
vs control, 54.8 ± 7.6, P < .001, one-way ANOVA and two-sided t 
test, three independent experiments; Supplementary Figure 6, D, 
available online) than had been evident with the SMARTpool 
siRNA were observed. Upon depletion of ABCC4 in SH-SY5Y 
cells using SMARTpool siRNA (Figure 4, A), the results obtained 
were entirely consistent with those observed in the BE(2)-C cell 
line. Thus, ABCC4 suppression resulted in a substantial increase 
in the proportion of cells extending neuritic processes, despite the 
high basal level of neurites for this cell line (mean % neurite- 
positive cells ± 95% CI: ABCC4, 39.5 ± 6.7 vs control, 24.0 ± 4.5, 
P = .01, two-sided Student t test, three independent experiments; 
Figure 4, B). This increased morphological differentiation was 
accompanied by statistically significantly reduced thymidine incor-
poration (mean % of control ± 95% CI: ABCC4, 68.1 ± 13.1, P = 
.02, one-sample Student t test, three independent experiments; 
Figure 4,C) and colony-forming ability (mean number of colonies ± 
95% CI: ABCC4, 98.1 ± 16.3 vs control, 143.2 ± 10.8, P = .004, two-
sided Student t test, three independent experiments; Figure 4, D). 
Finally, we examined the effect of pharmacological inhibition of 
ABCC4 on the behavior of BE(2)-C cells. Although there is a cur-
rent lack of potent and specific ABCC4 inhibitors, we have identi-
fied, through chemical small-molecule library screening, a number 
of compounds that sensitize ABCC4-overexpressing cells to the 
well-characterized ABCC4 substrate, 6-mercaptopurine (6-MP), 
and that enhance 14C-6-MP accumulation in these cells. 
Importantly, among these compounds, we have identified at least 
two that substantially reduce the growth of BE(2)-C cells and 
enhance their neurite formation (data not shown), thus closely 
recapitulating the effects of siRNA-mediated ABCC4 depletion.
Together, these data indicate that in the absence of chemother-
apeutic agents, modulation of ABCC1 or ABCC4 can influence 
multiple neuroblastoma cell characteristics relevant to tumor 
progression.
ABCC Family Gene Expression and Outcome in Primary 
Neuroblastoma
In addition to ABCC1, other members of the C branch of the ABC 
transporter family expel both cytotoxic drugs and a range of 
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Figure 3. Impact of ABCC1 modulation in SH-SY5Y and SH-EP neuro-
blastoma cells. A) Western blot analysis of ABCC1 protein expression 
following stable transduction of SH-SY5Y cells with either empty 
vector, wild-type (wt) ABCC1 (clones D5, H7), ABCC1 D1454N single 
mutant (clone B4), or ABCC1 DD1454LL double mutant (clone B7) con-
structs. Refer to Supplementary Figure 1 (available online) for verifica-
tion of membrane-localized transporter expression. B) Representative 
images of wound closure assay; Scale bar = 125 µm. C) Expression of 
ABCC1-wt and motility of SH-SY5Y cells, as measured by wound clo-
sure assay for 24 hours, compared with catalytically inactive mutants. 
D) Quantification of colony-forming assay upon expression of ABCC1-wt 
or catalytically inactive mutants in SH-SY5Y cells. In panels (C) and (D), 
one-way analysis of variance followed by two-sided t tests vs control 
were used to generate P values. E) Western blot analysis of ABCC1 
protein expression following exposure of SH-EP cells to ABCC1-specific 
siRNA, or to control siRNA. F) Representative images of wound closure 
assay; Scale bar = 125 µm. G) Quantification indicating impaired wound 
closure ability upon ABCC1 suppression. H) ABCC1 depletion and 
impaired colony-forming ability. I, J) Wound closure and K) colony-
forming abilities of SH-EP cells upon pharmacological inhibition of 
ABCC1 using 5 µM Reversan. Means displayed in all panels are derived 
from at least three independent experiments except for the clonogenic-
ity assay of siRNA-transfected SH-EP cells (H), which was derived from 
two independent experiments, each with two internal replicates. In 
panels (G), (J), and (K), P values were derived from the two-sided 
Student t test vs control. Error bars represent 95% confidence intervals. 
ABCC1 = ATP-binding cassette, subfamily C, member 1; DMSO, dimethyl 
sulfoxide; siRNA = short interfering RNA.
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endogenous substrates that are capable of influencing tumor 
behavior [reviewed in (11,31,32)]. Having established that ABCC1 
can affect the behavior of neuroblastoma cells both in vitro and 
in vivo and that ABCC4 can also influence neuroblastoma cell 
Figure 4. Impact of ABCC4 suppression in SH-SY5Y neuroblastoma 
cells. A) Western blot analysis of ABCC4 protein expression following 
exposure of SH-SY5Y cells to ABCC4-specific SMARTpool siRNA, or to 
control siRNA. B) Enhanced neurite extension in SH-SY5Y cells upon 
depletion of ABCC4. C) 3H-thymidine incorporation in SH-SY5Y cells 
depleted of ABCC4. D) Clonogenic capacity upon depletion of ABCC4 
was assayed after 12 days. In panel (B) and (D), P values were derived 
from two-sided Student t test vs control, whereas one-sample t test was 
used in panel (C) (H0, µ = 100%). Means are derived from three replicate 
experiments and error bars represent 95% confidence intervals. ABCC4 
= ATP-binding cassette, subfamily C, member 4; siRNA = short inter-
fering RNA.
Table 1. Clinical and molecular characteristics of neuroblastoma patient tumors*
Clinical characteristic
No. of patients
MYCN amplification ABCC1 expression ABCC3 expression ABCC4 expression
Present Absent High Low High Low High Low
Age†
 <1 y 3 93 12 84 87 8 9 87
 >1 y 20 91 8 104 67 45 11 101
Tumor stage‡
 Favorable 1 105 8 98 87 18 6 100
 Unfavorable 22 65 12 76 56 32 14 74
* Two hundred and nine study patients; Categories are overlapping. MYCN amplification was considered absent if there were nine or fewer FISH signals for MYCN 
per tumor cell and present if there were more than nine signals. Status of two case patients was unknown. For ABCC1 and ABCC4, the level of expression was 
considered high or low in relation to the upper decile of DDCt values for all tumors analyzed. For ABCC3, the level of expression was considered high or low in 
relation to the lower quartile of DDCt values for all tumors analyzed. DDCt method is the comparative threshold cycle method of transcript quantification. ABCC = 
ATP-binding cassette, subfamily C; FISH = Fluorescence in situ hybridization; MYCN = v-myc myelocytomatosis viral related oncogene, neuroblastoma derived.
† Age (categorized as <1 or >1 year at diagnosis) was statistically significantly associated with MYCN amplification (P < .001) and with ABCC3 expression (P < 
.001) (Two-sided Fisher exact tests). Age was unknown for one patient.
‡ Tumor stage was categorized as favorable (INSS stages 1, 2A/2B, or 4S) or unfavorable (INSS stages 3 or 4) and was unknown in 15 case patients. Tumor stage 
was statistically significantly associated with MYCN amplification (P < .001), ABCC3 expression (P = .003), and ABCC4 expression (P = .03) (Two-sided Fisher’s 
exact tests). INSS = International Neuroblastoma Staging System.
characteristics, we assessed whether the expression of other ABCC 
family members was associated with clinical outcome in this 
disease and whether their effects might be independent of cyto-
toxic drug efflux. We therefore analyzed the expression of the 
remaining ABCC family members (including ABCC4, which had 
previously been investigated only in a small retrospective study) in 
209 prospectively accrued primary neuroblastomas (refer  to Materials 
and Methods and Supplementary Figure 3, available online, for 
cohort description). Initial examination of ABCC gene family mem-
bers revealed that expression levels of ABCC6, ABCC7, and 
ABCC10–12 were either extremely low or undetectable in a repre-
sentative subset of neuroblastoma samples. These genes were not 
examined further. Expression levels of the remaining genes, ABCC2-5 
and ABCC8-9, were determined for the entire neuroblastoma 
cohort by real-time polymerase chain reaction.
Like ABCC1, which we previously showed to be highly 
expressed in tumors with MYCN amplification (5,6), we found 
statistically significantly higher levels of ABCC4 expression in neu-
roblastomas with MYCN amplification (n = 23), compared with 
those without MYCN amplification (n = 184) (mean DDCt ± 95% 
CI: MYCN-amplified, 962 ± 495.9 vs MYCN nonamplified, 96 ± 
21.6, P < .001, two-sided Student t test). ABCC4 expression was 
also associated with advanced tumor stage (Table 1; P = .03). We 
also observed a strong inverse association between ABCC3 expres-
sion and advanced tumor stage (Table 1; P = .003) and also older 
age at diagnosis (Table 1; P < .001). Expression of ABCC8 and 
ABCC9 was associated with MYCN amplification (mean DDCt 
ABCC8 ± 95% CI: MYCN-amplified, 53 ± 33.3 vs MYCN nonam-
plified, 29 ± 6.9, P = .04, and mean DDCt ABCC9 ± 95% CI: 
MYCN-amplified, 5.2 ± 7.3 vs MYCN nonamplified, 3.9 ± 0.33, 
P = .02, two-sided Student t tests). Whereas expression of ABCC2, 
ABCC5, and ABCC9 was associated with older age at diagnosis 
(Supplementary Table 2, available online), there were no associa-
tions between expression of ABCC2, ABCC5, or ABCC8-9 and 
tumor stage (Supplementary Table 2, available online).
As previously described for this cohort, ABCC1 expression was found 
to be strongly associated with outcome following dichotomization 
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around the upper decile (5). Using this same cut point, high 
ABCC4 expression was also strongly associated with reduced 
event-free survival (HR = 4.7, 95% CI = 2.5 to 8.9; P < .001) and 
overall survival (HR = 5.4, 95% CI = 2.8 to 10.4; P < .001; Table 2 
and Supplementary Figure 7, A, available online), consistent with 
earlier findings in a smaller separate cohort (12). Again, none of 
the patients in this study were treated with any cytotoxic drugs that 
are substrates of ABCC4. Similar results were obtained when the 
data were dichotomized using the mean or upper quartile as cut 
points (data not shown). In contrast, low levels, rather than high 
levels, of ABCC3 expression were strongly associated with reduced 
event-free survival (HR = 2.4, 95% CI = 1.4 to 4.2; P = .001) and 
reduced overall survival (HR = 2.4, 95% CI = 1.3 to 4.3; P = .003; 
Table 2 and  Supplementary Figure 7, D, available online), with 23 
of 53 patients with low ABCC3 expression experiencing recurrence 
or death compared with 31 of 155 patients with high ABCC3. This 
result remained statistically significant whether the upper quartile, 
median, or lower quartile was used for dichotomization, with 
the lower quartile maximally differentiating outcome of patients. 
No other ABCC genes predicted outcome, regardless of the cut 
point used (Supplementary Table 3, available online).
ABCC1 expression was highly prognostic in subsets of patients 
expected to have either particularly poor or particularly good out-
come (5). Extending this observation, in patients with advanced 
disease (stages 3 and 4), high ABCC4 or low ABCC3 expression was 
associated with statistically significantly worse outcome (% 5-year 
event-free survival ± 95% CI: high ABCC4, 21 ± 43.1 vs low 
ABCC4, 54 ± 23.5, P < .001 and % 5-year event-free survival ± 95% 
CI: low ABCC3, 34 ± 33.3 vs high ABCC3, 57 ± 25.5, P = .03; 
Supplementary Figure 7, B and E, available online). Similarly, for 
patients without MYCN amplification, low-level ABCC4 or 
high-level ABCC3 expression was associated with better outcome 
compared with patients having high ABCC4 or low ABCC3 expres-
sion (% 5-year event-free survival ± 95% CI: high ABCC4, 53 ± 
66.6 vs low ABCC4, 80 ± 11.8, P = .022 and % 5-year event-free 
survival: low ABCC3, 63 ± 27.4 vs high ABCC3, 84 ± 13.7, 
P = .0016; Supplementary Figure 7, C and F, available online).
In testing for the independent prognostic significance of 
ABCC1, ABCC3, and ABCC4 gene expression in a model with 
tumor stage, age, and MYCN amplification, only stage (HR of re-
currence or death = 4.5, 95% CI = 2.1 to 9.9; P < .001) and the three 
ABCC genes (HR, high ABCC1 = 2.3, 95% CI = 1 to 5; P = .04; low 
ABCC3 = 2.3, 95% CI = 1.2 to 4.4; P = .01; high ABCC4 = 3.1, 95% 
CI = 1.2 to 7.7, P = .02) remained associated with event-free survival 
(Table 2). Age and MYCN amplification were not independently 
statistically significant in this model. The only factors that retained 
independent prognostic significance for overall survival were tumor 
stage (HR of death = 9.5, 95% CI = 3.2 to 27.6; P < .001) and 
ABCC4 expression (HR of death = 3.2, 95% CI = 1.2 to 8.3; P = .02).
Given the strong association between altered expression of 
these three transporters and clinical outcome, we examined the 
prognostic value of their combined expression pattern. In this 
analysis, there were eight possible combinations based on high or 
low expression of the three genes. These eight combinations were 
descriptively compared with Kaplan–Meier curves, and clusters 
were recategorized into groups, such that curves not statistically 
significantly different from one another were included in the same 
group (Figure 5, A). These statistical groupings were subsequently 
found to accurately reflect biological risk associated with ABCC 
gene expression. Group A included only those patients whose 
tumors displayed low levels of ABCC1 and ABCC4 and high levels 
of ABCC3, reflecting “favorable” ABCC gene expression. The 5-
year cumulative event-free survival rate of this group was 85% 
(95% CI = 77% to 90%). Group B consisted of patients whose 
tumors displayed only one unfavorable risk factor with respect to 
the three ABCC genes analyzed (ie, ABCC1 high, ABCC4 high, or 
ABCC3 low), and the event-free survival rate of this group was 
60% (95% CI = 47% to 71%). Group C was found to comprise 
patients whose tumors exhibited two or more unfavorable ABCC 
risk factors, and the event-free survival rate of patients in this 
Table 2. Univariate and multivariable Cox regression analysis of factors prognostic for outcome in neuroblastoma*
Factor
Event-free survival Overall survival
HR (95% CI)† P‡ HR(95% CI) P‡
Univariate
 High ABCC1 expression (n = 209) 3.8 (2.0 to 7.2) <.001 3.4 (1.7 to 6.8) .001
 Low ABCC3 expression (n = 208) 2.4 (1.4 to 4.2) .001 2.4 (1.3 to 4.3) .003
 High ABCC4 expression (n = 209) 4.7 (2.5 to 8.9) <.001 5.4 (2.8 to 10.4) <.001
Multivariable (n = 192)§
 High ABCC1 expression 2.3 (1.0 to 5.0) .04 1.7 (0.7 to 3.9) .21
 Low ABCC3 expression 2.3 (1.2 to 4.4) .01 1.9 (1.0 to 3.8) .06
 High ABCC4 expression 3.1 (1.2 to 7.7) .02 3.2 (1.2 to 8.3) .02
 Advanced tumor stage 4.5 (2.1 to 9.9) <.001 9.5 (3.2 to 27.6) <.001
 Older age 1.8 (0.8 to 3.8) .14 2.1 (0.9 to 4.9) .10
 MYCN amplification 1.02 (0.5 to 2.3) .96 1.1 (0.5 to 2.6) .75
* MYCN amplification was considered absent if there were nine or fewer FISH signals for MYCN per tumor cell and present if there were more than nine signals. 
Status of two case patients was unknown. For ABCC1 and ABCC4, the level of expression was considered high or low in relation to the upper decile of DDCt 
values for all tumors analyzed. For ABCC3, the level of expression was considered high or low in relation to the lower quartile of DDCt values for all tumors 
analyzed. DDCt method is the comparative threshold cycle method of transcript quantification. ABCC = ATP-binding cassette, subfamily C; FISH = Fluorescence 
in situ hybridization; MYCN = v-myc myelocytomatosis viral related oncogene, neuroblastoma derived.
† Hazard ratios were calculated as the antilogs of the regression coefficients in the proportional hazards regression.
‡ Univariate: log-rank test; Multivariable: Cox model.
§ Multivariable analysis was performed following inclusion of all listed prognostic factors into the Cox regression model.
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group was 17% (95% CI = 3% to 41%). The combined expression 
of ABCC1, ABCC3, and ABCC4 was associated with patients 
having an adverse event, such that of the 12 patients with the “poor 
prognosis” expression pattern, 10 experienced recurrence or death. 
Figure 5. Prognostic significance of ABCC gene expression in neuro-
blastoma. A) Combined expression of the ABCC1, ABCC3 and ABCC4 
genes and cumulative event-free survival (EFS) in 209 patients with 
neuroblastoma. Patients were categorized into eight clusters on the 
basis of their combined ABCC1, ABCC3, and ABCC4 expression pattern. 
Kaplan–Meier survival analysis of these clusters revealed three statisti-
cally distinct groupings (Groups A, B, and C), which were associated 
with the risk of relapse associated with individual ABCC gene expres-
sion. Group A included only those patients whose tumors displayed 
low levels of ABCC1 and ABCC4 and high levels of ABCC3, reflecting 
“favorable” ABCC gene expression. Group B consisted of patients 
whose tumors displayed only one unfavorable risk factor with respect 
to the three ABCC genes analyzed (ie, ABCC1 high, ABCC4 high, or 
ABCC3 low), and Group C comprised patients whose tumors exhibited 
two or more unfavorable ABCC risk factors. Similar associations 
between combined ABCC gene expression and increasingly poor out-
come were also observed in subgroups of patients (B) with stage 3 or 4 
disease or (C) whose tumors lacked MYCN amplification. D) Combined 
expression of the ABCC1, ABCC3, and ABCC4 genes and cumulative 
EFS in 251 neuroblastoma patient samples analyzed by Oberthuer et al. 
(27). Patients in the Oberthuer et al. (27) cohort were categorized into 
eight groups as described for panel (A) above. These groupings were 
also strongly predictive of EFS in subgroups of patients (E) with unfa-
vorable (stages 3 and 4) disease or (F) with non–MYCN-amplified 
disease. At 0, 3, and 6 years from diagnosis [Panels (A), (B), and (C)], or 
0, 5, and 10 years from diagnosis [Panels (D), (E), and (F)], the number 
of patients at risk of relapse are shown. ABCC = ATP-binding cassette, 
subfamily C; MYCN = v-myc myelocytomatosis viral related oncogene, 
neuroblastoma derived.
Patients in this group were 12 times more likely to have an adverse 
event (HR of recurrence or death = 12.3; 95% CI = 6 to 27; P < 
.001). Combined ABCC gene expression was also analyzed in sub-
groups of patients with unfavorable (stages 3 and 4) disease (Figure 
5, B) or without MYCN amplification (Figure 5, C) and found for 
each case to be highly prognostic of outcome. The risk of an adverse 
event for Group C patients was high in both subgroups with a 
hazard ratio of 6.4 (95% CI = 3 to 15; P < .001) for patients with 
stage 3 or 4 tumors and 13.9 (95% CI = 5 to 42; P < .001) for 
patients without MYCN amplification.
Multivariable analysis of combined expression of the ABCC1, 
ABCC3, and ABCC4 genes, including tumor stage, age, and MYCN 
amplification as variables, revealed stage and unfavorable expres-
sion of one (Group B) or more (Group C) ABCC genes as indepen-
dent indicators of event-free survival, with the hazard ratio for an 
adverse event in Group B being 2.05 (95% CI = 1 to 4; P = .033) 
and in Group C being 5.02 (95% CI = 2 to 14; P = .001).
Validation of Prognostic Significance of ABCC1, ABCC3, 
and ABCC4 in an Independent Dataset
To verify the prognostic significance of ABCC gene expression in 
an independent cohort, we analyzed a publicly available dataset 
from Oberthuer et al. (27) containing clinical, pathological, and 
gene expression data for 251 primary neuroblastoma tumors. From 
this dataset, normalized expression data generated by custom oligo-
nucleotide microarray hybridization were extracted for ABCC1, 
ABCC3, and ABCC4 and the association with clinical outcome 
examined. Again, high expression of either ABCC1 (HR of recur-
rence or death = 4.7; 95% CI = 2.7 to 8.1; P < .001) or ABCC4 
(HR = 3.95; 95% CI = 2.3 to 6.8; P < .001) was strongly associated 
with reduced event-free survival, as was low expression of ABCC3 
(HR = 3.35; 95% CI = 1.9 to 5.95; P < .001). Furthermore, when 
patients were grouped according to the combined expression pat-
tern of ABCC1, ABCC3, and ABCC4 as described above, these 
groupings were again found to distinguish good, intermediate, and 
poor patient outcome (Figure 5, D). Five-year cumulative event-
free survival was 77% (95% CI = 70% to 83%) in Group A, which 
included only those patients whose tumors displayed low levels of 
ABCC1 and ABCC4 and high levels of ABCC3 reflecting favorable 
ABCC gene expression, whereas event-free survival in Group B was 
41% (95% CI = 19% to 63%) and in Group C only 22% (95% 
CI = 2.4 to 41%; P < .001). These groupings were also strongly 
predictive of event-free survival in subgroups of patients with unfa-
vorable (stages 3 and 4) disease (Group A = 57% [95% CI = 44% 
to 71%], Group B = 30% [95% CI = 4.2% to 55%], Group C = 
24% [95% CI = 2.9% to 45%], P < .001; Figure 5, E) or with 
non–MYCN-amplified disease (Group A = 77% [95% CI = 71% to 
84%], Group B = 45% [95% CI = 18% to 72%], Group C = 0% 
[95% CI = 0% to 0%], P < .001; Figure 5, F). Of the other ABCC 
genes examined, expression data for ABCC2 and ABCC8 were also 
available in this dataset. Consistent with our study, neither of these 
genes was statistically significantly associated with patient outcome.
ABCC3 Expression and Neuroblastoma Cell Characteristics
Surprisingly, the analysis of ABCC gene expression in two 
independent cohorts of neuroblastoma patients demonstrated a 
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powerful independent association between low levels of ABCC3 
expression and clinical outcome. Although patients in both cohorts 
were treated with etoposide (5,27,33), an ABCC3 substrate, only 
an association between high-level expression of an ABCC family 
member and poor clinical outcome could be explained in terms of 
enhanced drug transport mediating chemotherapeutic drug resis-
tance and hence clinical outcome.
To investigate the significance of low ABCC3 expression in 
neuroblastoma, BE(2)-C cells, which have extremely low endoge-
nous levels of ABCC3, were transduced to constitutively express 
ABCC3. Stable clones expressing ABCC3 (Figure 6, A) displayed 
substantially impaired cellular migratory activity, as measured by 
wound closure ability (mean % of wound open ± 95% CI: ABCC3 
B12 wt, 55.0 ± 9.0 or ABCC3 A12 wt, 50.5 ± 4.5 vs empty vector, 
1.5 ± 2.0, P < .001, one-way ANOVA and two-sided t test, three 
independent experiments; Figure 6, B and C), and reduced colony-
forming capacity (mean number of colonies ± 95% CI: ABCC3 
B12 wt, 75.1 ± 2.35 or ABCC3 A12 wt, 73.9 ± 2.7 vs empty vector, 
90.9 ± 9.4, P =.03, one-way ANOVA and two-sided t test, three 
independent experiments; Figure 6, C), although no statistically 
significant impact on cell proliferation was observed (mean % of 
empty vector ± 95% CI: ABCC3 B12 wt, 83.4 ± 9.0; ABCC3 A12 
wt, 87.6 ± 9.6, P = .22, one-way ANOVA, three independent ex-
periments, Figure 6, E). Similar results were obtained upon stable 
expression of ABCC3 in mass-transfected pools (Supplementary 
Figure 8, available online). ABCC3 transport activity is necessary 
for the observed effects on cell motility and clonogenicity, because 
the wound closure and colony-forming ability of cells expressing 
catalytically inactive ABCC3 (ABCC3-V1322F) were indistin-
guishable from cells transfected with empty vector (mean % 
of wound open ± 95% CI: ABCC3 C4, 5.4 ± 4.3 vs ABCC3 D1, 
3.0 ± 2.4 vs empty vector, 1.5 ± 2.0, P = .34, one-way ANOVA, 
three independent experiments; Figure 6, C and mean numberof 
colonies ± 95% CI: ABCC3 C4, 91.1 ± 6.5 vs ABCC3 D1, 92.0 ± 
7.4 vs empty vector, 90.9 ± 9.4, P = .98, one-way ANOVA, three 
independent experiments; Figure 6, D).
Collectively, these data clearly indicate that ABCC1, ABCC3, 
and ABCC4 have the ability to affect multiple aspects of tumor cell 
Figure 6. Impact of ABCC3 gene expression 
on human BE(2)-C neuroblastoma cell char-
acteristics. A) Western blot analysis of 
ABCC3 protein expression following stable 
transduction of BE(2)-C cells with either 
empty vector, wild-type (wt) ABCC3 (clones 
A12, B12) or ABCC3 V1322F mutant (clones 
C4, D1) constructs. Refer to Supplementary 
Figure 2 (available online) for verification of 
membrane-localized transporter expression. 
B) Representative images of wound closure 
assay; Scale bar, 125 µm. C) Expression of 
ABCC3-wt and impaired motility of BE(2)-C 
cells, as measured by wound closure assay 
for 24 hours, compared with catalytically in-
active mutant. D) Colony-forming assay and 
E) Bromodeoxyuridine (BrdU) incorporation 
upon expression of ABCC3-wt or catalytically 
inactive mutant in BE(2)-C cells. One-way 
analysis of variance followed by two-sided 
t tests vs control were used to generate 
P values. Means are derived from three rep-
licate experiments and error bars represent 
95% confidence intervals. ABCC3 = ATP-
binding cassette, subfamily C, member 3.
1248   Articles | JNCI Vol. 103, Issue 16  |  August 17, 2011
phenotype, independent of any role in cytotoxic drug efflux and 
drug resistance.
Discussion
Although several studies suggest that ABC drug transporters 
contribute to tumor progression independent of their drug efflux 
capabilities [reviewed in (11)], the evidence has remained essen-
tially correlational to date. The current study provides direct ge-
netic evidence that an ABC transporter, ABCC1, can contribute to 
tumor development in a mouse cancer model. Furthermore, this 
study demonstrates that high-level expression of ABCC4 and 
low-level expression of ABCC3 are both highly associated with 
clinical outcome in patients with neuroblastoma, a result not 
accounted for by the cytotoxic drug efflux capacities of either 
protein. The combined expression of ABCC1, ABCC3, and 
ABCC4 stratified patients into groups having excellent, interme-
diate, or poor outcome, and this combination of factors is one of 
the most powerful independent prognostic markers yet, to our 
knowledge, identified for this disease. Finally, this study demon-
strates that each of these transporters affects multiple character-
istics of cultured neuroblastoma cells, providing initial insights 
into the physiological function of these transporters beyond 
drug efflux.
The ABCC branch of the ABC transporter superfamily con-
tains several transporters known to confer cellular resistance to 
clinically important chemotherapeutic agents (9). The best charac-
terized of these, ABCC1, transports several classes of chemothera-
peutic drugs commonly used in the treatment of neuroblastoma 
including Vinca alkaloids, epipodophyllotoxins, and anthracyclines. 
We found that pharmacological inhibition of ABCC1 using 
Reversan, or deletion of one Abcc1 allele, delays tumor formation 
in the hMYCN transgenic mouse model of neuroblastoma in the 
absence of antineoplastic agents. Consistent with this observation, 
siRNA-mediated depletion of ABCC1 or inhibition of ABCC1 
with Reversan in neuroblastoma cell lines impaired cell motility 
and clonogenic capacity, also in the absence of chemotherapeutic 
agents. These results reinforce earlier observations in which intro-
duction of antisense mRNA to ABCC1 into neuroblastoma cells 
resulted in reduced cell growth and increased apoptosis in cell 
culture or cell line xenograft models (29,34). Conversely, forced 
high-level expression of ABCC1 enhanced cell migratory ability 
and clonogenic ability, with these effects shown to be dependent 
on the ATP-driven efflux capacity of ABCC1. Together, these 
results provide compelling evidence for a role for ABCC1-
mediated efflux of endogenous cellular substrates in neuroblas-
toma biology.
We have now found high ABCC4 expression to be strongly 
predictive of poor outcome in three independent cohorts. In con-
trast to the broad substrate specificity of ABCC1, ABCC4 overex-
pression has been shown to confer resistance only to nucleoside 
analogs and topoisomerase poisons, such as camptothecin, irinote-
can, and topotecan (9,35,36), none of which were used to treat the 
patients within any of these cohorts. In addition, this study identi-
fied low, rather than high, expression of ABCC3 as being predictive 
of poor outcome, despite the ability of ABCC3 to expel the impor-
tant neuroblastoma chemotherapeutic, etoposide. Consistent with 
these observations, siRNA-mediated silencing of ABCC4 using 
either SMARTpool siRNA or either of two independent siRNA 
duplexes in two different neuroblastoma cell lines, led to an 
increase in morphological differentiation and reduced growth 
capacity, with these effects being faithfully recapitulated by chemical 
small molecules that inhibit ABCC4-mediated drug efflux. By 
comparison, the most prominent phenotype associated with 
ABCC1 modulation was altered cell motility, with little impact on 
morphological differentiation. Although depletion of either gene 
impaired colony-forming ability, suggesting that these proteins 
may share some functions, ABCC4 modulation had a substantially 
more pronounced effect on proliferation, as measured by 
3H-thymidine or BrdU incorporation, perhaps pointing to distinct 
mechanisms. Consistent with low-level expression of ABCC3 being 
associated with poor clinical outcome in neuroblastoma, overex-
pression of ABCC3 led to decreased cell motility and colony for-
mation, with these effects again being shown to be dependent on 
the catalytic activity of ABCC3 and suggesting involvement of 
efflux of cellular substrates important to neuroblastoma biology. 
The finding that forced expression of ABCC3 mirrored the effects 
of ABCC1 depletion suggests opposing roles for these proteins in 
neuroblastoma.
Thus, although high ABCC1 expression in neuroblastoma can 
clearly contribute to the chemoresistant behavior of this tumor 
through enhanced drug efflux (5,10), our data provide compelling 
evidence for an additional and more direct contribution to tumor 
growth and progression. The prognostic power of high ABCC4 
expression and low ABCC3 expression for poor outcome, together 
with the inability of known cytotoxic drug substrates to account for 
these associations in the cohorts studied, as well as the impact of 
modified expression of these genes on neuroblastoma cell pheno-
types, all suggest that these transporters may also contribute to 
neuroblastoma biology and clinical outcome independently of 
drug efflux. Crossbreeding experiments between MYCN trans-
genic mice and Abcc3 and Abcc4 gene knockout models, paralleling 
those already undertaken with Abcc1 knockout mice, are the essen-
tial next steps to determine the true biological impact of these two 
transporters in neuroblastoma development, progression, and 
treatment response in vivo. These studies are currently underway 
and will be important in validating these genes as worthwhile ther-
apeutic targets for this disease.
Although the mechanisms underlying these observations are at 
present unknown, the efflux of endogenous substrates seems to be 
the most probable. ABCC1 expels a diverse range of physiological 
substrates including folates, phosphosphingolipids, glutathione, 
leukotrienes, and glutathione conjugates of steroids, many of 
which have established roles in tumor development and progres-
sion, and the activities of this transporter are important in a range 
of normal cellular processes such as export of endogenous interme-
diates and protection from toxic insult [see (11,37) for recent 
reviews]. Recently, ABCC1 was found to play a role in migration 
of thyroid carcinoma cells by mediating efflux of the inflammatory 
mediator sphingosine-1-phosphate (38) and was responsible for 
mediating the antiapoptotic effects of glucocorticoids in human 
fibroblasts by promoting sphingosine-1-phosphate efflux (39). 
Mice lacking ABCC1 display an altered response to inflammatory 
stimuli, most likely attributable to decreased secretion of the 
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proinflammatory cytokine leukotriene C4, which has the highest 
affinity for ABCC1 of any known transporter substrate (40). An 
association between chronic inflammation and cancer has long 
been observed, and the products of arachidonic acid metabolism, 
including leukotrienes and prostaglandins, appear to be involved in 
both inflammatory processes and cancer cell growth (37,41). 
Notably, blocking arachidonic acid metabolism through the use of 
nonsteroidal anti-inflammatory drugs has been shown to inhibit 
neuroblastoma cell growth both in vitro and in vivo (42). In light 
of the known physiological roles of ABCC1, it was interesting to 
observe that the protective effect of deletion of one allele of Abcc1 
in the MYCN transgenic model of neuroblastoma tumorigenesis 
was not augmented by deletion of the second Abcc1 allele. This 
effect could be attributed to compensatory increased expression of, 
for example, one of the many other ABC transporter genes or else 
could represent haploinsufficiency, if loss of only one allele was 
sufficient to bring about the maximal phenotype. However, it is 
also possible that the effect is associated with the putative role for 
ABCC1 in dendritic cell homing to lymph nodes, which may in 
turn play a critical role in tumor surveillance (40,43). This hypo-
thesis deserves further attention because it has implications for the 
development of clinical strategies for targeted inhibition of 
ABCC1 and potentially other ABC transporters.
ABCC4 can mediate the low-affinity transport of cyclic- 
nucleotides (cGMP and cAMP) (44), which are key effectors of 
G-protein-coupled receptors that regulate multiple aspects of cell 
growth. In cultured neuroblastoma cells, elevation of cAMP levels 
leads to decreased growth and increased morphological differenti-
ation (45,46). Alternately, as with ABCC1, in vivo and in vitro 
models have shown that ABCC4 mediates transport of inflamma-
tory mediators such as prostaglandins, leukotrienes, and conju-
gated steroids (47–49). This transporter has a major functional role 
in the efflux of prostaglandin E2 (18), which is known to influence 
diverse cellular processes involved in inflammation, as well as neo-
plastic transformation and progression (50,51).
Conversely, the strong association of low ABCC3 expression 
with poor clinical outcome suggests that ABCC3 may be trans-
porting an endogenous substrate inhibitory to neuroblastoma 
growth and metastasis. Consistent with this, ABCC3 expression is 
induced in the presence of nonsteroidal anti-inflammatory drugs 
or glucocorticoids (52,53), suggesting that it may play a role in the 
anti-inflammatory response. Candidate mediators might include 
conjugated steroids, which are substrates of ABCC3 (54). 
Dampened efflux of an antiproliferative or anti-inflammatory 
mediator might be expected to contribute to a proinflammatory 
environment otherwise promoted by high levels of ABCC1 and 
ABCC4.
The coordinate expression of high levels of ABCC1 and 
ABCC4 and low levels of ABCC3 in poor outcome neuroblastoma 
is likely to reflect a common regulatory mechanism. We have re-
cently found that MYCN positively regulates the expression of 
ABCC1 and ABCC4, and negatively regulates ABCC3, but does 
not regulate other members of the ABCC subfamily (8). Direct 
regulation by MYCN raises the possibility that these transporters 
are important contributors to a transcriptional program that 
facilitates development of aggressive treatment-refractory 
neuroblastoma.
A limitation of this study is that although robust cellular phe-
notypes are observed upon suppression of ABCC4 or enhanced 
expression of ABCC3 in vitro, the implications for neuroblastoma 
tumor biology remain to be confirmed in vivo. In this respect, in 
vivo experiments analogous to those presented here for ABCC1 
are currently being undertaken. Also, although each of these trans-
porters clearly can contribute to various cellular phenotypes, the 
precise cellular mechanisms by which they do so are still the sub-
ject of ongoing studies.
In conclusion, our results indicate that ABCC1 contributes to 
the development of neuroblastoma in a mouse model and suggest 
that this occurs through contributions to fundamental processes 
within the tumor cell, independent of its established drug efflux 
role. Furthermore, our results suggest that ABCC4 and ABCC3 
also contribute directly to neuroblastoma outcome, again indepen-
dent of drug efflux. Given the powerful prognostic significance of 
these three ABCC genes, further investigation of their fundamen-
tal roles in tumor biology is clearly warranted, and with the current 
and evolving use of ABCC1 and ABCC4 substrate drugs in neuro-
blastoma, a case is building for development of targeted therapeu-
tics against these transporters or against pathways associated with 
their biological functions. Elucidation of such pathways is the sub-
ject of ongoing studies aimed at identifying the precise endoge-
nous substrates responsible for the observed effects on 
tumorigenesis and neuroblastoma cell biology. This study also 
highlights the advantages of broadening expression studies beyond 
those ABC transporters expected to mediate drug resistance in a 
particular tumor type.
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